Pancreatic Cancer Research

ResearcherUniversity of FreiburgNo recent work listed

Sven Arke Lang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4455-5676; OpenAlex author ID A5087276676, A5104110046. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers

Papers 8

  1. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. Co-author DOI 10.1038/s41388-020-01578-4↗
  2. Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. Co-author DOI 10.3390/jcm10030490↗
  3. Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models. Last author DOI 10.18632/oncotarget.15524↗
  4. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. Last author DOI 10.1186/s12885-015-1064-9↗
  5. STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. Last author DOI 10.1593/neo.12878↗
  6. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. First author PMID 22753713↗
  7. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.01917.x↗
  8. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Last author DOI 10.1158/1535-7163.mct-11-0312↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiuxiang Tan · 2 shared papers, 2021 · strength 0.21
  2. Lara Rosaline Heij · 2 shared papers, 2021 · strength 0.21
  3. Steven W.M. Olde Damink · 2 shared papers, 2021 · strength 0.21
  4. Merel R. Aberle · 2 shared papers, 2021 · strength 0.21
  5. Georg J. Wiltberger · 2 shared papers, 2021 · strength 0.21
  6. Shivan Sivakumar · 2 shared papers, 2021 · strength 0.21
  7. Christina Hackl · 3 shared papers, 2012–2017 · strength 0.13
  8. Katharina Maria Schmidt · 2 shared papers, 2015–2017 · strength 0.12
  9. Christian Moser · 4 shared papers, 2011–2012 · strength 0.11
  10. Gregory van der Kroft · 1 shared paper, 2021 · strength 0.10
  11. Dominik Paul Modest · 1 shared paper, 2021 · strength 0.10
  12. Tom Luedde · 1 shared paper, 2021 · strength 0.10
  13. Anjali A. Roeth · 1 shared paper, 2021 · strength 0.10
  14. Judith de Vos‐Geelen · 1 shared paper, 2021 · strength 0.10
  15. Oliver Stoeltzing · 3 shared papers, 2011–2012 · strength 0.09
  16. Christoph W. Michalski · 1 shared paper, 2017 · strength 0.07
  17. Bo Kong · 1 shared paper, 2017 · strength 0.07
  18. Franziska Brandes · 1 shared paper, 2015 · strength 0.06
  19. Karl‐Hermann Schlingensiepen · 1 shared paper, 2011 · strength 0.03
  20. Anneliese Schneider · 1 shared paper, 2011 · strength 0.03
  21. Johannes Taeger · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.